Nadiye Akdeniz1, Muhammet Ali Kaplan2, Mehmet Küçüköner2, Zuhat Urakçı2, Şahin Laçin3, Emre Hüsnü Ceylan4, Abdurrahman Işıkdoğan2. 1. Department of Medical Oncology, Adiyaman Training and Research Hospital, Adiyaman, Turkey. nadiyeakdeniz21@gmail.com. 2. Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey. 3. Department of Medical Oncology, Faculty of Medicine, Yeditepe University, İstanbul, Turkey. 4. Department of Physical Education, Batman University, Batman, Turkey.
Abstract
BACKGROUND: Positive effects of exercise in cancer patients have been reported. AIM: To investigate whether intensity, duration, and timing of exercise affect disease relapse and mortality risk in patients with breast cancer (BC). METHODS: Patients with local or locally advanced stages of BC between January 2018 and January 2020 were recruited in the study. Sociodemographic and clinicopathological characteristics of patients were recorded. Exercise evaluation was performed by preparing a questionnaire and asking the patients face-to-face questions in the outpatient clinic. RESULTS: Risk of relapse was 58% lower in patients who exercised than inactive patients (p = 0.004). Patients who exercised for 2 to 5 days per week had a 63% lower relapse risk than inactive patients (p = 0.010). Risk of relapse was 66% lower in the patients who exercised for less than 1 h or 3 metabolic equivalent of task (MET)-hours per week when compared to inactive patients (p = 0.037). Similarly, relapse risk was 62% lower in patients who exercised between 1 to 3 h or 3 to 8.9 MET-hours per week than inactive patients (p = 0.026). Mortality risk was lower in patients who exercised than patients who did not (p = 0.027). A significantly decreased mortality risk was found in both groups that included patients who exercised for 1 to 5 days per week and patients who exercised for less than 3 h or 9 MET-hours per week when compared to inactive patients. CONCLUSION: Exercise was associated with decreased relapse and mortality rates in patients with BC. Therefore, exercise should be recommended to BC patients as a significant component of the treatment.
BACKGROUND: Positive effects of exercise in cancer patients have been reported. AIM: To investigate whether intensity, duration, and timing of exercise affect disease relapse and mortality risk in patients with breast cancer (BC). METHODS: Patients with local or locally advanced stages of BC between January 2018 and January 2020 were recruited in the study. Sociodemographic and clinicopathological characteristics of patients were recorded. Exercise evaluation was performed by preparing a questionnaire and asking the patients face-to-face questions in the outpatient clinic. RESULTS: Risk of relapse was 58% lower in patients who exercised than inactive patients (p = 0.004). Patients who exercised for 2 to 5 days per week had a 63% lower relapse risk than inactive patients (p = 0.010). Risk of relapse was 66% lower in the patients who exercised for less than 1 h or 3 metabolic equivalent of task (MET)-hours per week when compared to inactive patients (p = 0.037). Similarly, relapse risk was 62% lower in patients who exercised between 1 to 3 h or 3 to 8.9 MET-hours per week than inactive patients (p = 0.026). Mortality risk was lower in patients who exercised than patients who did not (p = 0.027). A significantly decreased mortality risk was found in both groups that included patients who exercised for 1 to 5 days per week and patients who exercised for less than 3 h or 9 MET-hours per week when compared to inactive patients. CONCLUSION: Exercise was associated with decreased relapse and mortality rates in patients with BC. Therefore, exercise should be recommended to BC patients as a significant component of the treatment.
Authors: Barbara E Ainsworth; William L Haskell; Stephen D Herrmann; Nathanael Meckes; David R Bassett; Catrine Tudor-Locke; Jennifer L Greer; Jesse Vezina; Melicia C Whitt-Glover; Arthur S Leon Journal: Med Sci Sports Exerc Date: 2011-08 Impact factor: 5.411
Authors: Elisa V Bandera; Stephanie H Fay; Edward Giovannucci; Michael F Leitzmann; Rachel Marklew; Anne McTiernan; Amy Mullee; Isabelle Romieu; Inger Thune; Ricardo Uauy; Martin J Wiseman Journal: Int J Cancer Date: 2016-07-13 Impact factor: 7.396
Authors: Diego Lugo; Alma L Pulido; Christos G Mihos; Omar Issa; Mike Cusnir; Sofia A Horvath; Jeffrey Lin; Orlando Santana Journal: Complement Ther Med Date: 2019-03-20 Impact factor: 2.446
Authors: Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes Journal: J Clin Oncol Date: 2006-12-11 Impact factor: 44.544
Authors: M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Lisa A Cadmus Bertram; Marcia L Stefanick; Nazmus Saquib; Loki Natarajan; Ruth E Patterson; Wayne Bardwell; Shirley W Flatt; Vicky A Newman; Cheryl L Rock; Cynthia A Thomson; John P Pierce Journal: Cancer Causes Control Date: 2010-12-24 Impact factor: 2.506